What is the total value and structure of Lilly's acquisition of AtaiBeckley, and what key asset does it gain?

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, consisting of a $2.8 billion upfront cash payment and up to $1 billion in milestone-based payments. The deal gives Lilly access to AtaiBeckley's lead candidate, BPL-003 — a psychedelic-based nasal spray in late-stage development for treatment-resistant depression.

Why is Lilly entering the psychedelic drug space now, and how does this fit into its broader strategic priorities?

Lilly is entering the psychedelic drug race to expand its neuroscience pipeline and diversify beyond its cornerstone cardiometabolic franchise, particularly its obesity drugs. This acquisition follows its $7.8 billion purchase of Centessa Pharmaceuticals in June and aligns with its strategy to invest in high-need areas like mental health, supported by recent U.S. policy momentum — including President Trump’s April directive to accelerate regulatory review and increase federal funding for psychedelic research.

Lilly Enters Psychedelic Drug Race with Up to $3.8 Billion AtaiBeckley Deal

Jul 16, 2026

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion to access its lead psychedelic candidate BPL-003 for treatment-resistant depression. The deal marks Lilly's latest move into neuroscience amid growing industry interest in psychedelic mental health therapies.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026